Clinical Trials Browser

Active not recruiting × INDUSTRY × Multiple Myeloma × Clear all

NCT05317416 2026-04-16

MagnetisMM-7

Phase 3 Active not recruiting

Hematologic Diseases, Multiple Myeloma

NCT06550895 2026-04-14

MonumenTAL-8

Phase 2 Active not recruiting

Multiple Myeloma

NCT03901963 2026-04-13

AURIGA

Phase 3 Active not recruiting

200 enrolled 12 charts

Multiple Myeloma

NCT04108195 2026-04-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04133636 2026-04-13

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT04181827 2026-04-13

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT04722146 2026-04-13

MajesTEC-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT04923893 2026-04-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT05050097 2026-04-13

MonumenTAL-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 2 FDA

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05675449 2026-04-13

MagnetisMM-20

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT05955508 2026-04-13

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06425991 2026-04-13

MajesTEC-10

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT06577025 2026-04-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT04684108 2026-04-07

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Phase 1 Active not recruiting

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT04975997 2026-04-03

EXCALIBER-RRMM

Phase 3 Active not recruiting

Multiple Myeloma

NCT05552976 2026-04-01

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT04162210 2026-03-31

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT06223516 2026-03-27

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04756726 2026-03-25

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Phase 1 Active not recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT05742217 2026-03-23

MUST

Active not recruiting

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1/2 Active not recruiting

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT03844048 2026-03-20

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04910568 2026-03-19

CAMMA 1

Phase 1 Active not recruiting

Multiple Myeloma

NCT02952508 2026-03-18

CLOVER-WaM

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT03173092 2026-03-18

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Phase 4 Active not recruiting

Multiple Myeloma

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

Multiple Myeloma

NCT03741127 2026-03-04

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Phase 1 Active not recruiting

Multiple Myeloma

NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2 Active not recruiting

46 enrolled 15 charts

Multiple Myeloma

NCT05587972 2026-02-23

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

Phase NA Active not recruiting

BreastGastrointestinalPlasma cellThoracic

Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Multiple Myeloma

NCT05646836 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04977024 2026-02-11

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

COVID-19, Leukemia, Lymphoma, Multiple Myeloma

NCT05396885 2026-02-11

iMMagine-1

Phase 2 Active not recruiting

Multiple Myeloma

NCT05535244 2026-02-09

CAMMA 2

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT03933735 2026-02-06

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04586426 2026-01-16

RedirecTT-1

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT03246529 2026-01-15

GENESIS

Phase 3 Active not recruiting

180 enrolled 22 charts

Multiple Myeloma

NCT05954780 2026-01-14

SEATTLE

Active not recruiting

Multiple Myeloma

NCT05013190 2026-01-08

A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Active not recruiting

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

Phase 2 Active not recruiting

Multiple Myeloma

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT04184050 2025-12-05

MK-4002-001

Phase 1 Active not recruiting

Multiple Myeloma

NCT01838512 2025-12-02

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Active not recruiting

Multiple Myeloma